Takeda taking magnifying glass to non-viral gene therapy programs as Carmine pact ends
Takeda’s work in AAV gene therapy is ending, but the Japanese pharma is also taking a closer look at its non-viral approaches to the tough …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
